

# REZUROCK (belumosudil)

### **Pre - PA Allowance**

None

# **Prior-Approval Requirements**

**Age** 12 years of age or older

### **Diagnosis**

Patient must have the following:

- 1. Chronic graft-versus-host disease (cGVHD)
  - a. Patient has received at least two prior lines of systemic therapy

#### **AND ALL** of the following:

- a. Prescriber agrees to monitor AST, ALT, and bilirubin at least monthly
- Females of reproductive potential only: patient will be advised to use effective contraception during treatment with Rezurock and for 1 week after the last dose
- c. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Rezurock and for 1 week after the last dose

## **Prior - Approval Limits**

**Quantity** 180 tablets per 90 days

**Duration** 12 months

# Prior – Approval Renewal Requirements

**Age** 12 years of age or older

### **Diagnosis**

Patient must have the following:

1. Chronic graft-versus-host disease (cGVHD)

#### **AND ALL** of the following:

- a. NO disease progression or unacceptable toxicity
- b. Prescriber agrees to monitor AST, ALT, and bilirubin at least monthly



Federal Employee Program.

#### REZUROCK

#### (belumosudil)

- c. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Rezurock and for 1 week after the last dose
- d. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Rezurock and for 1 week after the last dose

# Prior - Approval Renewal Limits

Same as above